Cerebral Hypoperfusion and the Energy Deficit in Alzheimer's Disease

Brain Pathology

Volumn 26, Issue 5, 2016, Pages 607-617

  Love, Seth ^a   Miners, J Scott ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Alzheimer's disease; amyloid peptide; capillary damage; cerebral amyloid angiopathy; cholinergic innervation; endothelial nitric oxide synthase; endothelin 1; hypoperfusion; ischemia; renin angiotensin system; vascular dysfunction

Indexed keywords

AMYLOID BETA PROTEIN; ANGIOTENSIN II; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1;

ALZHEIMER DISEASE; ARTICLE; BIOACCUMULATION; BRAIN BLOOD VESSEL; BRAIN CAPILLARY; BRAIN CORTEX; BRAIN DAMAGE; BRAIN PERFUSION; CEREBROVASCULAR DISEASE; CHOLINERGIC SYSTEM; DENERVATION; ENERGY RESOURCE; HUMAN; HYPERTENSION; NONHUMAN; PRECUNEUS; VASCULAR AMYLOIDOSIS; VASOCONSTRICTION; WHITE MATTER;

EID: 84988650177     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/bpa.12401     Document Type: Article

References (151)

1. An SJ, Boyd R, Wang Y, Qiu X, Wang HD (2006) Endothelin-1 expression in vascular adventitial fibroblasts. Am J Physiol Heart Circ Physiol 290:H700–H708.
2. An SJ, Boyd R, Zhu M, Chapman A, Pimentel DR, Wang HD (2007) NADPH oxidase mediates angiotensin II-induced endothelin-1 expression in vascular adventitial fibroblasts. Cardiovasc Res 75:702–709.
3. Arvanitakis Z, Capuano AW, Leurgans SE, Buchman AS, Bennett DA, Schneider JA (2016) The relationship of cerebral vessel pathology to brain microinfarcts. Brain Pathol doi: 10.1111/bpa.12365.
4. Ashby EL, Love S, Kehoe PG (2012) Assessment of activation of the plasma kallikrein-kinin system in frontal and temporal cortex in Alzheimer's disease and vascular dementia. Neurobiol Aging 33:1345–1355.
5. Asllani I, Habeck C, Scarmeas N, Borogovac A, Brown TR, Stern Y (2008) Multivariate and univariate analysis of continuous arterial spin labeling perfusion MRI in Alzheimer's disease. J Cereb Blood Flow Metab 28:725–736.
6. Attems J, Jellinger KA (2004) Only cerebral capillary amyloid angiopathy correlates with Alzheimer pathology–a pilot study. Acta Neuropathol 107:83–90.
7. Baloyannis SJ, Baloyannis IS (2012) The vascular factor in Alzheimer's disease: a study in Golgi technique and electron microscopy. J Neurol Sci 322:117–121.
8. Barker R, Ashby EL, Wellington D, Barrow VM, Palmer JC, Kehoe PG et al (2014) Pathophysiology of white matter perfusion in Alzheimer's disease and vascular dementia. Brain 137:1524–1532.
9. Barker R, Wellington D, Esiri MM, Love S (2013) Assessing white matter ischemic damage in dementia patients by measurement of myelin proteins. J Cereb Blood Flow Metab 33:1050–1057.
10. Bell RD, Winkler EA, Sagare AP, Singh I, LaRue B, Deane R, Zlokovic BV (2010) Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron 68:409–427.
11. Benzinger TL, Blazey T, Jack CR, Jr., Koeppe RA, Su Y, Xiong C et al (2013) Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci U S A 110:E4502–E4509.
12. Binnewijzend MA, Kuijer JP, Benedictus MR, van der Flier WM, Wink AM, Wattjes MP et al (2013) Cerebral blood flow measured with 3D pseudocontinuous arterial spin-labeling MR imaging in Alzheimer disease and mild cognitive impairment: a marker for disease severity. Radiology 267:221–230.
13. Blin J, Ivanoiu A, Coppens A, De Volder A, Labar D, Michel C, Laterre EC (1997) Cholinergic neurotransmission has different effects on cerebral glucose consumption and blood flow in young normals, aged normals, and Alzheimer's disease patients. Neuroimage 6:335–343.
14. Borroni B, Perani D, Broli M, Colciaghi F, Garibotto V, Paghera B et al (2005) Pre-clinical diagnosis of Alzheimer disease combining platelet amyloid precursor protein ratio and rCBF spect analysis. J Neurol 252:1359–1362.
15. Bouras C, Kovari E, Herrmann FR, Rivara CB, Bailey TL, von Gunten A et al (2006) Stereologic analysis of microvascular morphology in the elderly: Alzheimer disease pathology and cognitive status. J Neuropathol Exp Neurol 65:235–244.
16. Brown DR, Hunter R, Wyper DJ, Patterson J, Kelly RC, Montaldi D, McCullouch J (1996) Longitudinal changes in cognitive function and regional cerebral function in Alzheimer's disease: a SPECT blood flow study. J Psychiatr Res 30:109–126.
17. Buee L, Hof PR, Bouras C, Delacourte A, Perl DP, Morrison JH, Fillit HM (1994) Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders. Acta Neuropathol 87:469–480.
18. Cadavid D, Mena H, Koeller K, Frommelt RA (2000) Cerebral β amyloid angiopathy is a risk factor for cerebral ischemic infarction. A case control study in human brain biopsies. J Neuropathol Exp Neurol 59:768–773.
19. Ceravolo R, Volterrani D, Tognoni G, Dell'Agnello G, Manca G, Kiferle L et al (2004) Cerebral perfusional effects of cholinesterase inhibitors in Alzheimer disease. Clin Neuropharmacol 27:166–170.
20. Challa VR, Thore CR, Moody DM, Anstrom JA, Brown WR (2004) Increase of white matter string vessels in Alzheimer's disease. J Alzheimers Dis 6:379–383.
21. Chalmers K, Wilcock GK, Love S (2003) APOE ε4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of A beta protein. Neuropathol Appl Neurobiol 29:231–238.
22. Chao LL, Buckley ST, Kornak J, Schuff N, Madison C, Yaffe K et al (2010) ASL perfusion MRI predicts cognitive decline and conversion from MCI to dementia. Alzheimer Dis Assoc Disord 24:19–27.
23. Charidimou A, Pantoni L, Love S (2016) The concept of sporadic cerebral small vessel disease: a road map on key definitions and current concepts. Int J Stroke 11:6–18.
24. Chen Y, Wolk DA, Reddin JS, Korczykowski M, Martinez PM, Musiek ES et al (2011) Voxel-level comparison of arterial spin-labeled perfusion MRI and FDG-PET in Alzheimer disease. Neurology 77:1977–1985.
25. Cipolla MJ (2009) Control of cerebral blood flow. In: The Cerebral Circulation, Chapter 5, pp. 41–52. Morgan & Claypool Life Sciences: San Rafael, CA.
26. Claassen JA, Jansen RW (2006) Cholinergically mediated augmentation of cerebral perfusion in Alzheimer's disease and related cognitive disorders: the cholinergic-vascular hypothesis. J Gerontol a Biol Sci Med Sci 61:267–271.
27. Cohen AD, Price JC, Weissfeld LA, James J, Rosario BL, Bi W et al (2009) Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve. J Neurosci 29:14770–14778.
28. Cohen Z, Bonvento G, Lacombe P, Hamel E (1996) Serotonin in the regulation of brain microcirculation. Prog Neurobiol 50:335–362.
29. Crawford F, Suo Z, Fang C, Mullan M (1998) Characteristics of the in vitro vasoactivity of β-amyloid peptides. Exp Neurol 150:159–168.
30. Dai W, Lopez OL, Carmichael OT, Becker JT, Kuller LH, Gach HM (2009) Mild cognitive impairment and alzheimer disease: patterns of altered cerebral blood flow at MR imaging. Radiology 250:856–866.
31. Davies P, Maloney AJ (1976) Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2:1403.
32. Dohi Y, Hahn AW, Boulanger CM, Buhler FR, Luscher TF (1992) Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries. Hypertension 19:131–137.
33. Dore-Duffy P, Wang S, Mehedi A, Katyshev V, Cleary K, Tapper A et al (2011) Pericyte-mediated vasoconstriction underlies TBI-induced hypoperfusion. Neurol Res 33:176–186.
34. Drake CT, Iadecola C (2007) The role of neuronal signaling in controlling cerebral blood flow. Brain Lang 102:141–152.
35. Dumas A, Dierksen GA, Gurol ME, Halpin A, Martinez-Ramirez S, Schwab K et al (2012) Functional magnetic resonance imaging detection of vascular reactivity in cerebral amyloid angiopathy. Ann Neurol 72:76–81.
36. Eckman EA, Adams SK, Troendle FJ, Stodola BA, Kahn MA, Fauq AH et al (2006) Regulation of steady-state β-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme. J Biol Chem 281:30471–30478.
37. Eckman EA, Reed DK, Eckman CB (2001) Degradation of the Alzheimer's amyloid β peptide by endothelin-converting enzyme. J Biol Chem 276:24540–24548.
38. Eckman EA, Watson M, Marlow L, Sambamurti K, Eckman CB (2003) Alzheimer's disease β-amyloid peptide is increased in mice deficient in endothelin-converting enzyme. J Biol Chem 278:2081–2084.
39. Elesber AA, Bonetti PO, Woodrum JE, Zhu XY, Lerman LO, Younkin SG, Lerman A (2006) Bosentan preserves endothelial function in mice overexpressing APP. Neurobiol Aging 27:446–450.
40. Elhusseiny A, Hamel E (2000) Muscarinic–but not nicotinic–acetylcholine receptors mediate a nitric oxide-dependent dilation in brain cortical arterioles: a possible role for the M5 receptor subtype. J Cereb Blood Flow Metab 20:298–305.
41. Ellis RJ, Olichney JM, Thal LJ, Mirra SS, Morris JC, Beekly D, Heyman A (1996) Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Neurology 46:1592–1596.
42. Esiri MM, Wilcock GK (1986) Cerebral amyloid angiopathy in dementia and old age. J Neurol Neurosurg Psychiatry 49:1221–1226.
43. Esiri MM, Wilcock GK, Morris JH (1997) Neuropathological assessment of the lesions of significance in vascular dementia. J Neurol Neurosurg Psychiatry 63:749–753.
44. Fergus A, Lee KS (1997) GABAergic regulation of cerebral microvascular tone in the rat. J Cereb Blood Flow Metab 17:992–1003.
45. Fischer VW, Siddiqi A, Yusufaly Y (1990) Altered angioarchitecture in selected areas of brains with Alzheimer's disease. Acta Neuropathol 79:672–679.
46. Gentile MT, Vecchione C, Maffei A, Aretini A, Marino G, Poulet R et al (2004) Mechanisms of soluble β-amyloid impairment of endothelial function. J Biol Chem 279:48135–48142.
47. Greer JM, Lees MB (2002) Myelin proteolipid protein–the first 50 years. Int J Biochem Cell Biol 34:211–215.
48. Hamel E (2004) Cholinergic modulation of the cortical microvascular bed. Prog Brain Res 145:171–178.
49. Hamilton NB, Attwell D, Hall CN (2010) Pericyte-mediated regulation of capillary diameter: a component of neurovascular coupling in health and disease. Front Neuroenergetics 2:5.
50. Haque SU, Dashwood MR, Heetun M, Shiwen X, Farooqui N, Ramesh B et al (2013) Efficacy of the specific endothelin a receptor antagonist zibotentan (ZD4054) in colorectal cancer: a preclinical study. Mol Cancer Ther 12:1556–1567.
51. Hunter JM, Kwan J, Malek-Ahmadi M, Maarouf CL, Kokjohn TA, Belden C et al (2012) Morphological and pathological evolution of the brain microcirculation in aging and Alzheimer's disease. PLoS One 7:e36893.
52. Jeynes B, Provias J (2009) Significant negative correlations between capillary expressed eNOS and Alzheimer lesion burden. Neurosci Lett 463:244–248.
53. Kakinuma Y, Furihata M, Akiyama T, Arikawa M, Handa T, Katare RG, Sato T (2010) Donepezil, an acetylcholinesterase inhibitor against Alzheimer's dementia, promotes angiogenesis in an ischemic hindlimb model. J Mol Cell Cardiol 48:680–693.
54. Kalaria RN, Cohen DL, Premkumar DR, Nag S, LaManna JC, Lust WD (1998) Vascular endothelial growth factor in Alzheimer's disease and experimental cerebral ischemia. Brain Res Mol Brain Res 62:101–105.
55. Kar S, Quirion R (2004) Amyloid β peptides and central cholinergic neurons: functional interrelationship and relevance to Alzheimer's disease pathology. Prog Brain Res 145:261–274.
56. Kehoe PG (2003) The renin-angiotensin-aldosterone system and Alzheimer s disease? J Renin Angiotensin Aldosterone Syst 4:80–93.
57. Kehoe PG, Miners S, Love S (2009) Angiotensins in Alzheimer's disease - friend or foe? Trends Neurosci 32:619–628.
58. Kehoe PG, Passmore PA (2012) The renin-angiotensin system and antihypertensive drugs in Alzheimer's disease: current standing of the angiotensin hypothesis? J Alzheimers Dis 30 Suppl 2:S251–S268.
59. Kehoe PG, Wilcock GK (2007) Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease? Lancet Neurol 6:373–378.
60. Kitaguchi H, Ihara M, Saiki H, Takahashi R, Tomimoto H (2007) Capillary beds are decreased in Alzheimer's disease, but not in Binswanger's disease. Neurosci Lett 417:128–131.
61. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K et al (2002) Apolipoprotein E ε4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 137:149–155.
62. Krick S, Hanze J, Eul B, Savai R, Seay U, Grimminger F et al (2005) Hypoxia-driven proliferation of human pulmonary artery fibroblasts: cross-talk between HIF-1α and an autocrine angiotensin system. FASEB J 19:857–859.
63. Krimer LS, Muly EC, 3rd, Williams GV, Goldman-Rakic PS (1998) Dopaminergic regulation of cerebral cortical microcirculation. Nat Neurosci 1:286–289.
64. Lamoke F, Mazzone V, Persichini T, Maraschi A, Harris MB, Venema RC et al (2015) Amyloid β peptide-induced inhibition of endothelial nitric oxide production involves oxidative stress-mediated constitutive eNOS/HSP90 interaction and disruption of agonist-mediated Akt activation. J Neuroinflammation 12:84.
65. Langbaum JB, Chen K, Caselli RJ, Lee W, Reschke C, Bandy D et al (2010) Hypometabolism in Alzheimer-affected brain regions in cognitively healthy Latino individuals carrying the apolipoprotein E ε4 allele. Arch Neurol 67:462–468.
66. Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, Havlik RJ (2000) Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging 21:49–55.
67. Lee S, Viqar F, Zimmerman ME, Narkhede A, Tosto G, Benzinger TL et al (2016) White matter hyperintensities are a core feature of Alzheimer's disease: evidence from the Dominantly Inherited Alzheimer Network. Ann Neurol (in press).
68. Liu AK, Chang RC, Pearce RKB, Gentleman SM (2015) Nucleus basalis of Meynert revisited: anatomy, history and differential involvement in Alzheimer's and Parkinson's disease. Acta Neuropathol 129:527–540.
69. Love S, Chalmers K, Ince P, Esiri M, Attems J, Jellinger K et al (2014) Development, appraisal, validation and implementation of a consensus protocol for the assessment of cerebral amyloid angiopathy in post-mortem brain tissue. Am J Neurodegener Dis 3:19–32.
70. Love S, Miners JS (2015) White matter hypoperfusion and damage in dementia: post-mortem assessment. Brain Pathol 25:99–107.
71. Love S, Miners JS (2016) Cerebrovascular disease in ageing and Alzheimer's disease. Acta Neuropathol 131:645–658.
72. Love S, Nicoll JA, Hughes A, Wilcock GK (2003) APOE and cerebral amyloid angiopathy in the elderly. Neuroreport 14:1535–1536.
73. Masuda J, Tanaka K, Ueda K, Omae T (1988) Autopsy study of incidence and distribution of cerebral amyloid angiopathy in Hisayama, Japan. Stroke 19:205–210.
74. Miners JS, Ashby E, Van Helmond Z, Chalmers KA, Palmer LE, Love S, Kehoe PG (2008) Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer's disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy. Neuropathol Appl Neurobiol 34:181–193.
75. Miners JS, Palmer J, Love S (in press) Pathophysiology of hypoperfusion of the precuneus in early Alzheimer's disease. Brain Pathol.
76. Miners JS, Palmer JC, Tayler H, Palmer LE, Ashby E, Kehoe PG, Love S (2014) Aβ degradation or cerebral perfusion? Divergent effects of multifunctional enzymes. Front Aging Neurosci 6:238.
77. Miners JS, van Helmond Z, Raiker M, Love S, Kehoe PG (2010) ACE variants and association with brain Aβ levels in Alzheimer's disease. Am J Transl Res 3:73–80.
78. Miners S, Ashby E, Baig S, Harrison R, Tayler H, Speedy E et al (2009) Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes. Am J Transl Res 1:163–177.
79. Mondello S, Buki A, Barzo P, Randall J, Provuncher G, Hanlon D et al (2014) CSF and plasma amyloid-β temporal profiles and relationships with neurological status and mortality after severe traumatic brain injury. Sci Rep 4:6446.
80. Montagne A, Barnes SR, Sweeney MD, Halliday MR, Sagare AP, Zhao Z et al (2015) Blood-brain barrier breakdown in the aging human hippocampus. Neuron 85:296–302.
81. Morris CD, Rose A, Curwen J, Hughes AM, Wilson DJ, Webb DJ (2005) Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence. Br J Cancer 92:2148–2152.
82. Morris MC, Scherr PA, Hebert LE, Glynn RJ, Bennett DA, Evans DA (2001) Association of incident Alzheimer disease and blood pressure measured from 13 years before to 2 years after diagnosis in a large community study. Arch Neurol 58:1640–1646.
83. Nagata K, Kondoh Y, Atchison R, Sato M, Satoh Y, Watahiki Y et al (2000) Vascular and metabolic reserve in Alzheimer's disease. Neurobiol Aging 21:301–307.
84. Nagata K, Sato M, Satoh Y, Watahiki Y, Kondoh Y, Sugawara M et al (2002) Hemodynamic aspects of Alzheimer's disease. Ann N Y Acad Sci 977:391–402.
85. Nation DA, Wierenga CE, Clark LR, Dev SI, Stricker NH, Jak AJ et al (2013) Cortical and subcortical cerebrovascular resistance index in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 36:689–698.
86. Niwa K, Carlson GA, Iadecola C (2000) Exogenous Aβ1-40 reproduces cerebrovascular alterations resulting from amyloid precursor protein overexpression in mice. J Cereb Blood Flow Metab 20:1659–1668.
87. Niwa K, Kazama K, Younkin L, Younkin SG, Carlson GA, Iadecola C (2002) Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am J Physiol Heart Circ Physiol 283:H315–H323.
88. Niwa K, Kazama K, Younkin SG, Carlson GA, Iadecola C (2002) Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol Dis 9:61–68.
89. Niwa K, Porter VA, Kazama K, Cornfield D, Carlson GA, Iadecola C (2001) Aβ-peptides enhance vasoconstriction in cerebral circulation. Am J Physiol Heart Circ Physiol 281:H2417–H2424.
90. Niwa K, Younkin L, Ebeling C, Turner SK, Westaway D, Younkin S et al (2000) Aβ1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proc Natl Acad Sci U S A 97:9735–9740.
91. Noll G, Wenzel RR, Luscher TF (1996) Endothelin and endothelin antagonists: potential role in cardiovascular and renal disease. Mol Cell Biochem 157:259–267.
92. Nor JE, Christensen J, Mooney DJ, Polverini PJ (1999) Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol 154:375–384.
93. Okazaki H, Reagan TJ, Campbell RJ (1979) Clinicopathologic studies of primary cerebral amyloid angiopathy. Mayo Clin Proc 54:22–31.
94. Pákáski M, Kálmán J (2008) Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease. Neurochem Int 53:103–111.
95. Palmer J, Love S (2011) Endothelin receptor antagonists: potential in Alzheimer's disease. Pharmacol Res 63:525–531.
96. Palmer JC, Baig S, Kehoe PG, Love S (2009) Endothelin-converting enzyme-2 is increased in Alzheimer's disease and up-regulated by Aβ. Am J Pathol 175:262–270.
97. Palmer JC, Barker R, Kehoe PG, Love S (2012) Endothelin-1 is elevated in Alzheimer's disease and upregulated by amyloid-β. J Alzheimers Dis 29:853–861.
98. Palmer JC, Tayler HM, Love S (2013) Endothelin-converting enzyme-1 activity, endothelin-1 production, and free radical-dependent vasoconstriction in Alzheimer's disease. J Alzheimers Dis 36:577–587.
99. Paris D, Humphrey J, Quadros A, Patel N, Crescentini R, Crawford F, Mullan M (2003) Vasoactive effects of Aβ in isolated human cerebrovessels and in a transgenic mouse model of Alzheimer's disease: role of inflammation. Neurol Res 25:642–651.
100. Paris D, Patel N, DelleDonne A, Quadros A, Smeed R, Mullan M (2004) Impaired angiogenesis in a transgenic mouse model of cerebral amyloidosis. Neurosci Lett 366:80–85.
101. Paris D, Town T, Parker TA, Humphrey J, Mullan M (1998) Isoform-specific vasoconstriction induced by apolipoprotein E and modulation of this effect by Alzheimer's β-amyloid peptide. Neurosci Lett 256:73–76.
102. Paris D, Townsend K, Quadros A, Humphrey J, Sun J, Brem S et al (2004) Inhibition of angiogenesis by Aβ peptides. Angiogenesis 7:75–85.
103. Park L, Anrather J, Zhou P, Frys K, Pitstick R, Younkin S et al (2005) NADPH-oxidase-derived reactive oxygen species mediate the cerebrovascular dysfunction induced by the amyloid β peptide. J Neurosci 25:1769–1777.
104. Park L, Zhou P, Pitstick R, Capone C, Anrather J, Norris EH et al (2008) Nox2-derived radicals contribute to neurovascular and behavioral dysfunction in mice overexpressing the amyloid precursor protein. Proc Natl Acad Sci U S A 105:1347–1352.
105. Patel NS, Mathura VS, Bachmeier C, Beaulieu-Abdelahad D, Laporte V, Weeks O et al (2010) Alzheimer's β-amyloid peptide blocks vascular endothelial growth factor mediated signaling via direct interaction with VEGFR-2. J Neurochem 112:66–76.
106. Paulson OB, Strandgaard S, Edvinsson L (1990) Cerebral autoregulation. Cerebrovasc Brain Metab Rev 2:161–192.
107. Peca S, McCreary CR, Donaldson E, Kumarpillai G, Shobha N, Sanchez K et al (2013) Neurovascular decoupling is associated with severity of cerebral amyloid angiopathy. Neurology 81:1659–1665.
108. Peppiatt CM, Howarth C, Mobbs P, Attwell D (2006) Bidirectional control of CNS capillary diameter by pericytes. Nature 443:700–704.
109. Power MC, Weuve J, Gagne JJ, McQueen MB, Viswanathan A, Blacker D Blood Pressure. The AlzRisk Database. Alzheimer Research Forum.
110. Power MC, Weuve J, Gagne JJ, McQueen MB, Viswanathan A, Blacker D (2011) The association between blood pressure and incident Alzheimer disease: a systematic review and meta-analysis. Epidemiology 22:646–659.
111. Premkumar DR, Cohen DL, Hedera P, Friedland RP, Kalaria RN (1996) Apolipoprotein E-ε4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. Am J Pathol 148:2083–2095.
112. Price JM, Sutton ET, Hellermann A, Thomas T (1997) β-amyloid induces cerebrovascular endothelial dysfunction in the rat brain. Neurol Res 19:534–538.
113. Raichle ME, Hartman BK, Eichling JO, Sharpe LG (1975) Central noradrenergic regulation of cerebral blood flow and vascular permeability. Proc Natl Acad Sci U S A 72:3726–3730.
114. Raja SG, Dreyfus GD (2008) Current status of bosentan for treatment of pulmonary hypertension. Ann Card Anaesth 11:6–14.
115. Reducing pathology in Alzheimer's disease through angiotensin targeting.
116. Rodrigue KM, Rieck JR, Kennedy KM, Devous MD, Sr., Diaz-Arrastia R, Park DC (2013) Risk factors for β-amyloid deposition in healthy aging: vascular and genetic effects. JAMA Neurol 70:600–606.
117. Rossi GP, Sacchetto A, Cesari M, Pessina AC Interactions between endothelin-1 and the renin-angiotensin-aldosterone system. Cardiovasc Res 43:300–307.
118. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A et al (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896–903.
119. Rubin LJ, Roux S (2002) Bosentan: a dual endothelin receptor antagonist. Expert Opin Investig Drugs 11:991–1002.
120. Sagare AP, Bell RD, Zhao Z, Ma Q, Winkler EA, Ramanathan A, Zlokovic BV (2013) Pericyte loss influences Alzheimer-like neurodegeneration in mice. Nat Commun 4:2932.
121. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH et al (1993) Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A 90:9649–9653.
122. Scott JA, Braskie MN, Tosun D, Thompson PM, Weiner M, DeCarli C, Carmichael OT Alzheimer's Disease Neuroimaging I (2015) Cerebral amyloid and hypertension are independently associated with white matter lesions in elderly. Front Aging Neurosci 7:221.
123. Sengillo JD, Winkler EA, Walker CT, Sullivan JS, Johnson M, Zlokovic BV (2013) Deficiency in mural vascular cells coincides with blood-brain barrier disruption in Alzheimer's disease. Brain Pathol 23:303–310.
124. Shimizu S, Hanyu H, Iwamoto T, Koizumi K, Abe K (2006) SPECT follow-up study of cerebral blood flow changes during Donepezil therapy in patients with Alzheimer's disease. J Neuroimaging 16:16–23.
125. Shin HK, Jones PB, Garcia-Alloza M, Borrelli L, Greenberg SM, Bacskai BJ et al (2007) Age-dependent cerebrovascular dysfunction in a transgenic mouse model of cerebral amyloid angiopathy. Brain 130:2310–2319.
126. Smith EE, Vijayappa M, Lima F, Delgado P, Wendell L, Rosand J, Greenberg SM (2008) Impaired visual evoked flow velocity response in cerebral amyloid angiopathy. Neurology 71:1424–1430.
127. Stow LR, Jacobs ME, Wingo CS, Cain BD (2011) Endothelin-1 gene regulation. Faseb J 25:16–28.
128. Suhara T, Magrane J, Rosen K, Christensen R, Kim HS, Zheng B et al (2003) Aβ42 generation is toxic to endothelial cells and inhibits eNOS function through an Akt/GSK-3beta signaling-dependent mechanism. Neurobiol Aging 24:437–451.
129. Tan XL, Xue YQ, Ma T, Wang X, Li JJ, Lan L et al (2015) Partial eNOS deficiency causes spontaneous thrombotic cerebral infarction, amyloid angiopathy and cognitive impairment. Mol Neurodegener 10:24.
130. Tarkowski E, Issa R, Sjogren M, Wallin A, Blennow K, Tarkowski A, Kumar P (2002) Increased intrathecal levels of the angiogenic factors VEGF and TGF-β in Alzheimer's disease and vascular dementia. Neurobiol Aging 23:237–243.
131. Tarumi T, Dunsky DI, Khan MA, Liu J, Hill C, Armstrong K et al (2014) Dynamic cerebral autoregulation and tissue oxygenation in amnestic mild cognitive impairment. J Alzheimers Dis 41:765–778.
132. Tayler HM, Palmer JC, Thomas TL, Kehoe PG, Paton JFR, Love S (2014) Investigating the relationship between cerebral Αβ and systemic hypertension [Abstract]. Neuropathol Appl Neurobiol 40:41.
133. Thal DR, Ghebremedhin E, Rub U, Yamaguchi H, Del Tredici K, Braak H (2002) Two types of sporadic cerebral amyloid angiopathy. J Neuropathol Exp Neurol 61:282–293.
134. Thomas T, Miners S, Love S (2015) Post-mortem assessment of hypoperfusion of cerebral cortex in Alzheimer's disease and vascular dementia. Brain 138:1059–1069.
135. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M (1996) Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 380:168–171.
136. Toews AD, White FV, Morell P (1988) Metabolism of functional groups modifying the CNS myelin-associated glycoprotein. J Neurochem 51:1646–1650.
137. Tohgi H, Yonezawa H, Takahashi S, Sato N, Kato E, Kudo M et al (1998) Cerebral blood flow and oxygen metabolism in senile dementia of Alzheimer's type and vascular dementia with deep white matter changes. Neuroradiology 40:131–137.
138. Tomonaga M (1981) Cerebral amyloid angiopathy in the elderly. J Am Geriatr Soc 29:151–157.
139. Tong XK, Hamel E (1999) Regional cholinergic denervation of cortical microvessels and nitric oxide synthase-containing neurons in Alzheimer's disease. Neuroscience 92:163–175.
140. Townsend KP, Obregon D, Quadros A, Patel N, Volmar C, Paris D, Mullan M (2002) Proinflammatory and vasoactive effects of Aβ in the cerebrovasculature. Ann N Y Acad Sci 977:65–76.
141. Tschope C, Schultheiss HP, Walther T (2002) Multiple interactions between the renin-angiotensin and the kallikrein-kinin systems: role of ACE inhibition and AT1 receptor blockade. J Cardiovasc Pharmacol 39:478–487.
142. Vaucher E, Hamel E (1995) Cholinergic basal forebrain neurons project to cortical microvessels in the rat: electron microscopic study with anterogradely transported Phaseolus vulgaris leucoagglutinin and choline acetyltransferase immunocytochemistry. J Neurosci 15:7427–7441.
143. Vinters HV, Gilbert JJ (1983) Cerebral amyloid angiopathy: incidence and complications in the aging brain. II. The distribution of amyloid vascular changes. Stroke 14:924–928.
144. Waite JJ, Holschneider DP, Scremin OU (1999) Selective immunotoxin-induced cholinergic deafferentation alters blood flow distribution in the cerebral cortex. Brain Res 818:1–11.
145. Winkler EA, Sagare AP, Zlokovic BV (2014) The pericyte: a forgotten cell type with important implications for Alzheimer's disease? Brain Pathol 24:371–386.
146. Yamada M, Tsukagoshi H, Otomo E, Hayakawa M (1987) Cerebral amyloid angiopathy in the aged. J Neurol 234:371–376.
147. Yan Z, Feng J (2004) Alzheimer's disease: interactions between cholinergic functions and β-amyloid. Curr Alzheimer Res 1:241–248.
148. Yang SP, Bae DG, Kang HJ, Gwag BJ, Gho YS, Chae CB (2004) Co-accumulation of vascular endothelial growth factor with β-amyloid in the brain of patients with Alzheimer's disease. Neurobiol Aging 25:283–290.
149. Zetterberg H, Mortberg E, Song L, Chang L, Provuncher GK, Patel PP et al (2011) Hypoxia due to cardiac arrest induces a time-dependent increase in serum amyloid β levels in humans. PLoS One 6:e28263.
150. Zhang ZG, Zhang L, Jiang Q, Zhang R, Davies K, Powers C et al (2000) VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest 106:829–838.
151. Zhu J, Song W, Li L, Fan X (2016) Endothelial nitric oxide synthase: a potential therapeutic target for cerebrovascular diseases. Mol Brain 9:30.